Indications for the drug Cadcyla
– treatment of patients with metastatic HER2-positive breast cancer previously treated with trastuzumab and a taxane (sequentially or in combination), who received prior treatment for metastatic disease, or who experienced disease progression during or within 6 months after completion of adjuvant therapy;
– adjuvant therapy for patients with early HER2-positive breast cancer and invasive residual tumor after neoadjuvant therapy with a taxane and trastuzumab.
Active ingredient: trasuzumab emtansine
100 Mg, 160 Mg